The potential of spironolactone to mitigate the risk of nonalcoholic fatty liver disease in hypertensive populations: evidence from a cohort study
This study demonstrates a significant association between spironolactone use and a reduced risk of NAFLD in hypertensive patients, suggesting that it may have potential dual benefits in managing hypertension and protecting liver health.
Authors
- Shuaiwei Song (ORCID: https://orcid.org/0009-0007-2444-2136)
- Xintian Cai (ORCID: https://orcid.org/0000-0003-3172-1540)
- Di Shen (ORCID: https://orcid.org/0009-0005-3689-7475)
- Rui Ma (ORCID: https://orcid.org/0000-0002-3884-8950)
- Nanfang Li (ORCID: https://orcid.org/0000-0003-1505-8566)
- Junli Hu (ORCID: https://orcid.org/0009-0009-2144-8289)
- Zhiqiang Zhang (ORCID: https://orcid.org/0000-0001-5418-3584)
- Yingying Zhang (ORCID: https://orcid.org/0009-0000-8795-8171)
- Jing Hong (ORCID: https://orcid.org/0009-0005-5320-487X)
- Qing Zhu (ORCID: https://orcid.org/0009-0001-0185-3086)
- Pan Zhou (ORCID: https://orcid.org/0000-0002-7105-6808)
Institutions
- People's Hospital of Xinjiang Uygur Autonomous Region (CN)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1097/meg.0000000000002986
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35